Anthony Sun, Zentalis and Zentera CEO (Zentalis)
With clinical trials lined up for Zentalis drugs, China's Zentera sets its sights on more dealmaking and an IPO
As Zentalis geared up for an AACR presentation of early data on its WEE1 inhibitor earlier this year, its Chinese joint venture Zentera wasn’t idle …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
